TECHNOLOGY

Targeted Nanoparticle Technology

With our proprietary technology platform, we are developing targeted nanoparticles with precise biophysicochemical properties optimized to deliver drugs for specific therapeutic applications. This technology concentrates the drug at the intended site of action while minimizing systemic exposure, thereby improving efficacy and reducing off-target effects. In order to deliver these important clinical benefits, the targeted nanoparticles need to be optimized across a set of biophysical properties in order to:

Evade the immune system
Bind to the target sites
Accumulate in the target tissue
Provide the desired drug release profile

Our technology platform provides BIND the unique capability to generate targeted nanoparticle libraries with distinct biophysicochemical properties, screen for nanoparticles with the optimal characteristics for the application, and reproducibly manufacture nanoparticles with those precise properties. BIND’s combinatorially optimized nanoparticles are designed to capitalize on both passive and active targeting mechanisms:

Passive – BIND's nanoparticles concentrate in areas of diseased tissue which are typically associated with “leaky” vasculature resulting in extravasation and nanoparticle accumulation.
Active - BIND's nanoparticles are designed to bind with high specificity and avidity to targeted cell-surface proteins or extracellular matrix components.

The fluorescence microscope image below reveals cytosolic accumulation through receptor mediated endocytosis of targeted nanoparticles specifically targeted to a cell-surface antigen:

Targeted Nanoparticle Platform

BIND’s targeted nanoparticles consist of the following components that facilitate optimization and control:

Targeting ligand provides recognition, enabling targeted nanoparticles to identify and bind to their intended target site. They are designed to recognize specific proteins or receptors that are found on the surface of cells involved in disease or the surrounding extracellular matrix.

Surface functionalization shields targeted nanoparticles from immune surveillance, while providing attachment for the targeting ligand through proprietary linkage strategies. We have developed proprietary methods for precisely controlling the surface characteristics necessary to ensure the drug is delivered efficiently and consistently.

Polymer matrix encapsulates payload molecules in a matrix of clinically validated biodegradable and biocompatible polymers that can be designed to provide the desired drug release profile.

Therapeutic payloads can be incorporated into our targeted nanoparticles, including small molecules, peptides, proteins and nucleic acids, such as siRNA.

Intellectual property

BIND's intellectual property portfolio consists of a broad patent estate of issued and pending patent applications covering long-circulating nanoparticles, targeted nanoparticles, controlled release polymer systems and nanoparticle synthesis. Key foundational intellectual property has been licensed on an exclusive and worldwide basis from MIT and Brigham and Women’s Hospital – Harvard Medical School.